vs
Side-by-side financial comparison of NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) and Xos, Inc. (XOS). Click either name above to swap in a different company.
Xos, Inc. is the larger business by last-quarter revenue ($5.2M vs $2.9M, roughly 1.8× NEUROONE MEDICAL TECHNOLOGIES Corp). NEUROONE MEDICAL TECHNOLOGIES Corp runs the higher net margin — -49.7% vs -186.8%, a 137.1% gap on every dollar of revenue. On growth, NEUROONE MEDICAL TECHNOLOGIES Corp posted the faster year-over-year revenue change (-11.7% vs -54.5%). Over the past eight quarters, NEUROONE MEDICAL TECHNOLOGIES Corp's revenue compounded faster (44.9% CAGR vs -35.7%).
NeuroOne Medical Technologies Corp is a medical technology company specializing in the development and commercialization of diagnostic and therapeutic neurological devices for conditions including epilepsy, movement disorders, and chronic pain. Its core products include minimally invasive cortical monitoring electrodes and neurostimulation systems, primarily serving neurology and neurosurgical care providers across North America.
Xos, Inc. is an American manufacturer of commercial electric vehicles (EVs) and mobile EV chargers.
NMTC vs XOS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.9M | $5.2M |
| Net Profit | $-1.4M | $-9.8M |
| Gross Margin | 54.2% | -50.5% |
| Operating Margin | -59.0% | -186.6% |
| Net Margin | -49.7% | -186.8% |
| Revenue YoY | -11.7% | -54.5% |
| Net Profit YoY | -180.5% | 48.6% |
| EPS (diluted) | $-0.03 | $-0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.9M | $5.2M | ||
| Q3 25 | $2.7M | $16.5M | ||
| Q2 25 | $1.7M | $18.4M | ||
| Q1 25 | $1.4M | $5.9M | ||
| Q4 24 | $3.3M | $11.5M | ||
| Q3 24 | $272.3K | $15.8M | ||
| Q2 24 | $825.8K | $15.5M | ||
| Q1 24 | $1.4M | $12.6M |
| Q4 25 | $-1.4M | $-9.8M | ||
| Q3 25 | $-1.6M | $2.1M | ||
| Q2 25 | $-1.5M | $-7.5M | ||
| Q1 25 | $-2.3M | $-10.2M | ||
| Q4 24 | $1.8M | $-19.0M | ||
| Q3 24 | — | $-10.5M | ||
| Q2 24 | $-2.8M | $-9.7M | ||
| Q1 24 | $-2.9M | $-11.0M |
| Q4 25 | 54.2% | -50.5% | ||
| Q3 25 | 55.8% | 15.3% | ||
| Q2 25 | 53.9% | 8.8% | ||
| Q1 25 | 55.6% | 20.6% | ||
| Q4 24 | 58.9% | -32.4% | ||
| Q3 24 | 51.8% | 18.1% | ||
| Q2 24 | 34.1% | 13.1% | ||
| Q1 24 | 28.3% | 22.1% |
| Q4 25 | -59.0% | -186.6% | ||
| Q3 25 | -50.0% | -42.4% | ||
| Q2 25 | -111.2% | -38.5% | ||
| Q1 25 | -193.3% | -157.7% | ||
| Q4 24 | 52.3% | -127.0% | ||
| Q3 24 | — | -61.4% | ||
| Q2 24 | -338.3% | -73.2% | ||
| Q1 24 | -209.5% | -81.1% |
| Q4 25 | -49.7% | -186.8% | ||
| Q3 25 | -59.1% | 12.9% | ||
| Q2 25 | -88.5% | -40.8% | ||
| Q1 25 | -163.8% | -173.3% | ||
| Q4 24 | 54.5% | -165.4% | ||
| Q3 24 | — | -66.6% | ||
| Q2 24 | -335.1% | -62.2% | ||
| Q1 24 | -207.3% | -87.1% |
| Q4 25 | $-0.03 | $-0.76 | ||
| Q3 25 | $-0.05 | $0.22 | ||
| Q2 25 | $-0.03 | $-0.91 | ||
| Q1 25 | $-0.07 | $-1.26 | ||
| Q4 24 | $0.06 | $-2.34 | ||
| Q3 24 | — | $-1.32 | ||
| Q2 24 | $-0.10 | $-1.23 | ||
| Q1 24 | $-0.11 | $-1.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.6M | $14.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.4M | $23.3M |
| Total Assets | $8.6M | $60.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.6M | $14.0M | ||
| Q3 25 | $6.6M | $14.1M | ||
| Q2 25 | $8.0M | $8.8M | ||
| Q1 25 | $1.3M | $4.8M | ||
| Q4 24 | $1.1M | $11.0M | ||
| Q3 24 | $1.5M | $8.4M | ||
| Q2 24 | $1.6M | $19.7M | ||
| Q1 24 | $2.4M | $46.2M |
| Q4 25 | $6.4M | $23.3M | ||
| Q3 25 | $7.1M | $31.1M | ||
| Q2 25 | $8.2M | $18.3M | ||
| Q1 25 | $1.1M | $24.8M | ||
| Q4 24 | $2.9M | $33.6M | ||
| Q3 24 | $822.0K | $50.8M | ||
| Q2 24 | $3.0M | $59.2M | ||
| Q1 24 | $3.9M | $67.8M |
| Q4 25 | $8.6M | $60.4M | ||
| Q3 25 | $10.8M | $73.8M | ||
| Q2 25 | $10.8M | $80.3M | ||
| Q1 25 | $4.5M | $87.7M | ||
| Q4 24 | $6.5M | $98.3M | ||
| Q3 24 | $5.4M | $120.5M | ||
| Q2 24 | $4.9M | $123.4M | ||
| Q1 24 | $5.4M | $135.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.1M | $2.4M |
| Free Cash FlowOCF − Capex | $-3.2M | — |
| FCF MarginFCF / Revenue | -109.1% | — |
| Capex IntensityCapex / Revenue | 1.4% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.1M | $2.4M | ||
| Q3 25 | $-1.5M | $3.1M | ||
| Q2 25 | $-1.5M | $4.6M | ||
| Q1 25 | $-56.1K | $-4.8M | ||
| Q4 24 | $208.0K | $3.3M | ||
| Q3 24 | $-11.0M | $-11.5M | ||
| Q2 24 | $-2.4M | $-26.0M | ||
| Q1 24 | $-2.2M | $-14.6M |
| Q4 25 | $-3.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $183.6K | — | ||
| Q3 24 | $-11.1M | $-11.7M | ||
| Q2 24 | $-2.4M | $-26.1M | ||
| Q1 24 | $-2.2M | $-14.6M |
| Q4 25 | -109.1% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -89.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 5.6% | — | ||
| Q3 24 | -4088.4% | -73.9% | ||
| Q2 24 | -287.6% | -168.1% | ||
| Q1 24 | -160.2% | -115.7% |
| Q4 25 | 1.4% | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 2.8% | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | 0.7% | 0.0% | ||
| Q3 24 | 44.1% | 0.9% | ||
| Q2 24 | 1.8% | 0.8% | ||
| Q1 24 | 2.3% | 0.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.45× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.12× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
